Yahoo Finance report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
Why TNON Stock dropped -5.85% Today — RQD Quant Desk Flash
Tenon Medical Inc. (TNON) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TNON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Tenon Medical Inc. (NASDAQ: TNON) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.93 (-5.85% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TNON ranks #814 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TNON compare to SNOA and INBS in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), TNON carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 59.8%, and ROIC of -35.0%. By comparison, SNOA (Sonoma Pharmaceuticals Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and INBS (Intelligent Bio Solutions Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M). Among the 5-stock peer group, TNON leads on earnings multiple (N/A) while TNON leads on capital efficiency (-35.0% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TNON?
▼
Per TNON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560293), Tenon Medical Inc. generated $3.9M in revenue (+20.4% YoY), -$12.6M in net income, and -$11.0M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.3 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
⚔️ Adversarial Opposing Case: What Could Spark a TNON Turnaround Squeeze
While TNON currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.42) and Max Pain ($2.03) forces dealer call-delta covering toward $47.77.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why TNON Stock dropped -5.85% Today — RQD Quant Desk Flash
Tenon Medical Inc. (TNON) dropped -5.85% to $1.93, trading at 2% of its 52-week range ($1.93 – $45.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.93 – $45.5) with RSI-14 at 34.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.93 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 59.8% gross margin and $0 annual free cash flow.
The Globe and Mail report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
~ New decortication system is the latest advancement in Tenon's next-generation SI joint fusion platform with additional innovative product launches expected in the coming quarters ~~ Quickstep Decorticator designed to s
Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients with sacro-pelvic disorders, today announced the completion of the initial alpha cases with its new
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TNON)
- ✓Walkthrough of TNON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
TNON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +20.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TNON today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TNON. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TNON)
1. Head-to-Head Health Care Peer Comparison (TNON vs. SNOA, INBS, NVNO, WOK)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Tenon Medical Inc. (TNON) ranks #814 by composite RQD confidence (30/100, grade E) and #935 by equity capitalization ($5.2M). Within this direct 5-issuer industry benchmark cohort, TNON leads on earnings valuation at N/A trailing P/E, while TNON leads on capital efficiency and profitability with -35.0% ROIC and 59.8% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with TNON at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TNON
ACTIVE
Tenon Medical Inc. | E | 30/100 | — | 59.8% | -35.0% | -5.85% | $5.2M | Benchmark Subject |
| SNOA Sonoma Pharmaceuticals Inc. | E | 34/100 | — | 38.0% | -35.0% | 0.00% | $5.3M | /snoa-vs-tnon → |
| INBS Intelligent Bio Solutions Inc. | E | 27/100 | — | 40.8% | -35.0% | -5.68% | $5.5M | /inbs-vs-tnon → |
| NVNO enVVeno Medical Corporation | E | 33/100 | — | — | -35.0% | +2.08% | $4.8M | /nvno-vs-tnon → |
| WOK WORK Medical Technology Group LTD (Class A) | D | 51/100 | — | — | — | 0.00% | $4.5M | /wok-vs-tnon → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001560293 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tenon Medical Inc. (TNON) reported GAAP revenue of $3.9M (+20.4% vs. FY2024 revenue of $3.3M , and +34.7% cumulative change since FY2023) , GAAP net income of -$12.6M, operating cash flow of -$10.7M, and free cash flow of -$11.0M (-9.5% YoY). On the balance sheet, TNON closed FY2025 with $10.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.9M | -$12.6M | -$10.7M | -$11.0M | $10.8M | — |
| FY2024 (FY) | 2024-12-31 | $3.3M | -$13.7M | -$9.9M | -$10.1M | $9.8M | — |
| FY2023 (FY) | 2023-12-31 | $2.9M | -$15.6M | -$12.2M | -$12.2M | — | — |
3. TNON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TNON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Tenon Medical Inc. (NASDAQ: TNON) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.93 (-5.85% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TNON ranks #814 in composite RQD confidence.
How does TNON compare to SNOA and INBS in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), TNON carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 59.8%, and ROIC of -35.0%. By comparison, SNOA (Sonoma Pharmaceuticals Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and INBS (Intelligent Bio Solutions Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M). Among the 5-stock peer group, TNON leads on earnings multiple (N/A) while TNON leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TNON?
Per TNON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560293), Tenon Medical Inc. generated $3.9M in revenue (+20.4% YoY), -$12.6M in net income, and -$11.0M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TNON trading relative to its 50-day, 200-day, and 52-week technical levels?
TNON last traded at $1.93 (-5.85% on volume of 61,387 shares), positioning the stock -43.57% below its 50-day simple moving average ($3.42) and -88.38% below its 200-day simple moving average ($16.61). Across its 52-week range of $1.93 to $45.50, TNON sits at the 0.0% percentile with a 14-day RSI of 34.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.69 to $2.17).
TNON — Tenon Medical Inc.: What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
Tenon Medical Inc. (TNON) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.93 (-5.85% 1D, market capitalization $5.2M).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 59.8%, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Tenon Medical Inc. (TNON) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. It is classified within these sector and industry categories. Per the market data, the company reports a gross margin of 59.8%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Tenon Medical Inc. (TNON) reported $3.9M in annual revenue (up from $3.3M in FY2024, +20.4% YoY) and -$12.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.9M revenue, -$15.6M net income) through FY2025, TNON scaled operating cash flow to -$10.7M and free cash flow to -$11.0M, backed by $10.8M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.93 – $45.50 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
— for upstream or downstream dependencies, sector correlations beyond the Health Care/Medical-Dental Instruments classification, or second-order bottlenecks.
- Key Question #1: Can TNON sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $3.9M and free cash flow of -$11.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is TNON's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
TNON Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Tenon Medical Inc. (TNON) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.
TNON Bull vs. Bear Conversation Board — What's Your Call at $1.93?
Revenue grew from $2.9M in FY 2023 to $3.9M in FY 2025 while the Altman Z-Score of 2.5 sits in the reported range.
Long TNON at $2.05 targeting $2.58. Revenue grew from $2.9M in FY 2023 to $3.9M in FY 2025 while the Altman Z-Score of 2.5 sits in the reported range.. Institutional whale score is 3/20 and the risk/reward vs. the $2.05 52-week low is skewed heavily in favor of bulls.
Both sides have a point here — TNON's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
ROIC of -35% and FCF of -$11.0M against cash of $3.8M point to a cash engine that is not self-funding and reliant on equity raises.
Here is the bear case nobody on the bull side wants to address on TNON: ROIC of -35% and FCF of -$11.0M against cash of $3.8M point to a cash engine that is not self-funding and reliant on equity raises.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.